Quote:

---

In addition to LymPro and our NuroPro Parkinson’s diagnostic, we are actively evaluating additional complementary late-stage neurology-focused diagnostic assets that would bolster our diagnostic division and make for a successful ‘spin-out’ while concurrently returning value to our shareholders. We believe we will be able to execute on this strategy in the near-term.

---

Quote:

---

As a holding company, our strategy is to acquire undervalued assets, incubate them through critical de-risking milestones and thereafter seek to deliver value to our shareholders through strategic initiatives.

---

Quote:

---

As we expect to soon derive value from our diagnostics division, we believe it will be important to replenish our pipeline with strategically positioned programs that have the potential to deliver significant return on investment for the company, as LymPro has.

---